{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:27:50Z","timestamp":1791318470906,"version":"4.3.1"},"reference-count":227,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.jim.2012.05.014","type":"journal-article","created":{"date-parts":[[2012,5,30]],"date-time":"2012-05-30T21:19:34Z","timestamp":1338412774000},"page":"1-23","source":"Crossref","is-referenced-by-count":65,"title":["Cancer therapy and vaccination"],"prefix":"10.1016","volume":"382","author":[{"given":"Hamdy A.A.","family":"Aly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2012.05.014_bb0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2007.03.005","article-title":"RNAi therapeutics: principles, prospects and challenges","volume":"59","author":"Aagaard","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jim.2012.05.014_bb0010","series-title":"Cellular and Molecular Immunology","author":"Abbas","year":"2007"},{"key":"10.1016\/j.jim.2012.05.014_bb0015","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ni1082","article-title":"Cellular mechanisms governing cross-presentation of exogenous antigens","volume":"5","author":"Ackerman","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb0020","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signalling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb0025","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.jim.2012.05.014_bb0030","series-title":"Molecular Biology of the Cell","author":"Alberts","year":"2002"},{"key":"10.1016\/j.jim.2012.05.014_bb0035","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.282.5392.1338","article-title":"Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking","volume":"282","author":"Alferink","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jim.2012.05.014_bb0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0268-960X(93)90025-Y","article-title":"The role of apoptosis (programmed cell death) in haemopoiesis and the immune system","volume":"7","author":"Allen","year":"1993","journal-title":"Blood Rev."},{"key":"10.1016\/j.jim.2012.05.014_bb0045","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1038\/sj.onc.1207113","article-title":"Survivin, versatile modulation of cell division and apoptosis in cancer","volume":"2253","author":"Altieri","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jim.2012.05.014_bb0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc2293","article-title":"Survivin, cancer networks and pathway-directed drug discovery","volume":"81","author":"Altieri","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jim.2012.05.014_bb0055","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/1078-0432.CCR-05-2013","article-title":"Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer","volume":"12","author":"Antonia","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0060","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/jnci\/djr244","article-title":"Mobile phone use and brain tumors in children and adolescents: a multicenter case\u2013control study","volume":"103","author":"Aydin","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jim.2012.05.014_bb0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0169-409X(98)00003-9","article-title":"Control of tumour vascular permeability","volume":"34","author":"Baban","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jim.2012.05.014_bb0075","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jim.2012.05.014_bb0070","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","article-title":"Immunobiology of dendritic cells","volume":"18","author":"Banchereau","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb0080","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jim.2012.05.014_bb0085","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.2005.11.890","article-title":"Critical update and emerging trends in epidermal growth factor receptor targeting in cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jim.2012.05.014_bb0090","first-page":"597","article-title":"Signal-induced site specific phosphorylation targets Bcl2 to the proteasome pathway","volume":"21","author":"Basu","year":"2002","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jim.2012.05.014_bb0095","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.nano.2008.06.002","article-title":"Emerging nanopharmaceuticals","volume":"4","author":"Bawarski","year":"2008","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jim.2012.05.014_bb0100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00262-008-0576-4","article-title":"Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy","volume":"25","author":"Baxevanis","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jim.2012.05.014_bb0105","first-page":"95","article-title":"Inhibition of DNA methylation by 5-aza-2\u2032\u2010deoxycytidine suppresses the growth of human tumor cell lines","volume":"58","author":"Bender","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"36","author":"Bergers","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jim.2012.05.014_bb0115","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.cell.2007.01.033","article-title":"The mammalian epigenome","volume":"128","author":"Bernstein","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.jim.2012.05.014_bb0120","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1158\/0008-5472.CAN-07-2822","article-title":"Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling","volume":"68","author":"Bicaku","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0125","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1038\/sj.onc.1206812","article-title":"The future of antisense therapy: combination with anticancer treatments","volume":"2242","author":"Biroccio","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jim.2012.05.014_bb0130","first-page":"2683","article-title":"Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis","volume":"97","author":"Blanc-Brude","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0135","first-page":"1172","article-title":"Antitumor vaccination: where we stand","volume":"85","author":"Bocchia","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.jim.2012.05.014_bb0140","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.addr.2004.02.014","article-title":"Nanoparticle and targeted systems for cancer therapy","volume":"56","author":"Brannon-Peppas","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jim.2012.05.014_bb0145","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1158\/0008-5472.CAN-06-4074","article-title":"The human let-7a-3 locus contains an epigenetically regulated micro\u2010RNA gene with oncogenic function","volume":"67","author":"Brueckner","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1479-5876-5-49","article-title":"The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo","volume":"5","author":"Buckley","year":"2007","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jim.2012.05.014_bb0155","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccr.2008.04.018","article-title":"Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression","volume":"13","author":"Bueno","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jim.2012.05.014_bb0160","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/oemed-2011-100155","article-title":"Risk of brain tumours in relation to estimated RF dose from mobile phones: results from five Interphone countries","volume":"68","author":"Cardis","year":"2011","journal-title":"Occup. Environ. Med."},{"key":"10.1016\/j.jim.2012.05.014_bb0165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1750-3639.2010.00426.x","article-title":"Role of cytotoxic protease granzyme-b in neuronal degeneration during human stroke","volume":"21","author":"Chaitanya","year":"2011","journal-title":"Brain Pathol."},{"key":"10.1016\/j.jim.2012.05.014_bb0170","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2174\/138920310791824057","article-title":"The ubiquitin\u2013proteasome system as a prospective molecular target for cancer treatment and prevention","volume":"11","author":"Chen","year":"2010","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.jim.2012.05.014_bb0175","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1586\/erv.09.11","article-title":"Novel strategies for improved cancer vaccines","volume":"8","author":"Chen","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.jim.2012.05.014_bb0180","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ccr.2004.06.023","article-title":"Preferential response of cancer cells to zebularine","volume":"6","author":"Cheng","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jim.2012.05.014_bb0185","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1158\/1535-7163.MCT-07-0172","article-title":"Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter","volume":"69","author":"Chun","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jim.2012.05.014_bb0190","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1158\/1535-7163.317.3.3","article-title":"Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy","volume":"3","author":"Chung","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jim.2012.05.014_bb0195","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00000658-192810000-00002","article-title":"End results in Hodgkin's disease and lymphosarcoma treated by the mixed toxins of Erysipelas and Bacillus prodigiosus, alone or combined with radiation","volume":"88","author":"Coley","year":"1928","journal-title":"Ann. Surg."},{"key":"10.1016\/j.jim.2012.05.014_bb0200","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/smll.200400093","article-title":"Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity","volume":"1","author":"Connor","year":"2005","journal-title":"Small"},{"key":"10.1016\/j.jim.2012.05.014_bb0205","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.jim.2012.05.014_bb0210","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.jim.2012.05.014_bb0215","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ctrv.2006.11.002","article-title":"Novel therapeutic targets in lung cancer: inhibitor of apoptosis proteins from laboratory to clinic","volume":"332","author":"Dean","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jim.2012.05.014_bb0220","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.4049\/jimmunol.178.9.5429","article-title":"Cutting edge: lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that suppress the CD8+ T cell response","volume":"178","author":"den Haan","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb0225","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1021\/jm800959f","article-title":"Efficient solid-phase synthesis of FK228 analogues as potent antitumoral agents","volume":"51","author":"Di Maro","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jim.2012.05.014_bb0230","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0140-6736(09)60404-9","article-title":"Use of tumour-responsive T cells as cancer treatment","volume":"373","author":"Disis","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jim.2012.05.014_bb0240","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1172\/JCI200422222","article-title":"Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis","volume":"1148","author":"Dohi","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jim.2012.05.014_bb0245","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc1252","article-title":"Cytokines in cancer pathogenesis and cancer therapy","volume":"4","author":"Dranoff","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jim.2012.05.014_bb0250","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","article-title":"Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity","volume":"90","author":"Dranoff","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jim.2012.05.014_bb0255","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00262-002-0309-z","article-title":"Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy","volume":"51","author":"Dredge","year":"2002","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jim.2012.05.014_bb0260","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0092-8674(00)00008-8","article-title":"Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition","volume":"1021","author":"Du","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.jim.2012.05.014_bb0265","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2006.12.020","article-title":"Survivin: a promising tumor biomarker","volume":"2491","author":"Duffy","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jim.2012.05.014_bb0270","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1158\/0008-5472.CAN-08-0946","article-title":"Antitumor effects of a combined 5-aza-2\u2032deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice","volume":"69","author":"Ecke","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0275","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","article-title":"Epigenetics in human disease and prospects for epigenetic therapy","volume":"429","author":"Egger","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jim.2012.05.014_bb0280","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.4049\/jimmunol.179.11.7295","article-title":"Ex vivo expansion of CD4+ CD25 + FoxP3 + T regulatory cells based on synergy between IL-2 and 4-1BB signaling","volume":"179","author":"Elpek","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb0285","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1018440801577","article-title":"Sunlight and cancer","volume":"8","author":"English","year":"1997","journal-title":"Cancer Causes Control"},{"issue":"10","key":"10.1016\/j.jim.2012.05.014_bb0290","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1084\/jem.20042167","article-title":"Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response","volume":"201","author":"Ercolini","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jim.2012.05.014_bb0295","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1146\/annurev.pharmtox.45.120403.095832","article-title":"Aberrant DNA methylation as a cancer-inducing mechanism","volume":"45","author":"Esteller","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jim.2012.05.014_bb0300","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2012.05.014_bb0305","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/10408360500523878","article-title":"Glutathione in cancer biology and therapy","volume":"43","author":"Estrela","year":"2006","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.jim.2012.05.014_bb0310","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","article-title":"A genetic model for colorectal tumorigenesis","volume":"61","author":"Fearon","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.jim.2012.05.014_bb0315","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/301089a0","article-title":"Hypomethylation distinguishes genes of some human cancers from their normal counterparts","volume":"301","author":"Feinberg","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.jim.2012.05.014_bb0320","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jim.2012.05.014_bb0325","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jim.2012.05.014_bb0330","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nrc1736","article-title":"Promoting apoptosis as a strategy for cancer drug discovery","volume":"511","author":"Fesik","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jim.2012.05.014_bb0335","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev.publhealth.26.021304.144445","article-title":"EMF and health","volume":"26","author":"Feychting","year":"2005","journal-title":"Annu. Rev. Public Health"},{"key":"10.1016\/j.jim.2012.05.014_bb0340","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1056\/NEJMra072739","article-title":"Cancer immunology","volume":"358","author":"Finn","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2012.05.014_bb0345","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/0008-5472.CAN-03-4061","article-title":"A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors","volume":"64","author":"Fraga","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.d6387","article-title":"Use of mobile phones and risk of brain tumours: update of Danish cohort study","volume":"343","author":"Frei","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jim.2012.05.014_bb0355","series-title":"Radiation Risk\/Radiation Protection","author":"Fritz-Niggi","year":"1991"},{"key":"10.1016\/j.jim.2012.05.014_bb0360","first-page":"11478","article-title":"DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations","volume":"90","author":"Fynan","year":"1993","journal-title":"Immunology"},{"key":"10.1016\/j.jim.2012.05.014_bb0365","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2567.2002.01471.x","article-title":"Regulation of tumour immunity by CD25+ T cells","volume":"107","author":"Gallimore","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.jim.2012.05.014_bb0370","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bpg.2006.01.003","article-title":"Prospects for vaccine therapy for pancreatic cancer","volume":"20","author":"Gaudernack","year":"2006","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.jim.2012.05.014_bb0375","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.addr.2008.03.016","article-title":"Gold nanoparticles in delivery applications","volume":"60","author":"Ghosh","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jim.2012.05.014_bb0380","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2005.08.409","article-title":"Epidermal growth factor receptor inhibitors in the treatment of non\u2010small-cell lung cancer","volume":"23","author":"Giaccone","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jim.2012.05.014_bb0385","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/TCRM.S856","article-title":"A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil)","volume":"4","author":"Govan","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.jim.2012.05.014_bb0390","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1006\/excr.2001.5187","article-title":"Histone acetylation and chromatin remodeling","volume":"265","author":"Gregory","year":"2001","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0395","doi-asserted-by":"crossref","first-page":"11276","DOI":"10.1073\/pnas.0804157105","article-title":"Immunochemical termination of self-tolerance","volume":"10","author":"Gr\u00fcnewald","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jim.2012.05.014_bb0400","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00262-004-0583-z","article-title":"A CD80-transfected human breast cancer cell variant induces HER-2\/neu-specific T cells in HLA-A\u204e02-matched situations in vitro as well as in vivo","volume":"54","author":"G\u00fcckel","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jim.2012.05.014_bb0405","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/1568009043332989","article-title":"Novel approaches for targeted cancer therapy","volume":"4","author":"Guillemard","year":"2004","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.jim.2012.05.014_bb0410","doi-asserted-by":"crossref","first-page":"B89","DOI":"10.1016\/j.vaccine.2007.04.091","article-title":"Enhancing efficacy of therapeutic vaccinations by combination with other modalities","volume":"25","author":"Gulley","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2012.05.014_bb0415","first-page":"1771","article-title":"Mobile phones and brain tumours \u2014 a scientific controversy","volume":"108","author":"Gunnarsson","year":"2011","journal-title":"Lakartidningen"},{"key":"10.1016\/j.jim.2012.05.014_bb0420","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1615\/CritRevImmunol.v21.i1-3.90","article-title":"Dendritic cells in cancer immunotherapy","volume":"21","author":"Gunzer","year":"2001","journal-title":"Crit. Rev. Immunol."},{"issue":"Suppl. 2","key":"10.1016\/j.jim.2012.05.014_bb0425","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1016\/S0167-8140(04)80046-X","article-title":"The Heidelberg Ion Therapy Center","volume":"73","author":"Haberer","year":"2004","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.jim.2012.05.014_bb0430","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1002\/anie.200600214","article-title":"Light regulated release of DNA and its delivery to nuclei by means of photolabile gold nanoparticles","volume":"45","author":"Han","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jim.2012.05.014_bb0435","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.jim.2012.05.014_bb0440","first-page":"319","article-title":"Importin beta: conducting a much larger cellular symphony","volume":"16","author":"Harel","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jim.2012.05.014_bb0445","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev.immunol.19.1.47","article-title":"Cross-presentation, dendritic cells, tolerance and immunity","volume":"19","author":"Heath","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb2005","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1016\/S0264-410X(03)00529-2","article-title":"Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus","volume":"21","author":"Hilleman","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2012.05.014_bb0455","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1513\/pats.200806-048LC","article-title":"Immunotherapy for lung cancer","volume":"6","author":"Hirschowitz","year":"2009","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.jim.2012.05.014_bb0450","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01243894-200601000-00019","article-title":"Vaccines for lung cancer","volume":"1","author":"Hirschowitz","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jim.2012.05.014_bb0460","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","article-title":"Cellular responses to viral infection in human: lessons from Epstein\u2013Barr virs","volume":"25","author":"Hislop","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb0465","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CMR.0b013e3282f702cf","article-title":"Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate","volume":"18","author":"Hofbauer","year":"2008","journal-title":"Melanoma Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0470","doi-asserted-by":"crossref","first-page":"10059","DOI":"10.1158\/0008-5472.CAN-05-1692","article-title":"Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity","volume":"65","author":"Hokey","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0475","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1098\/rstb.1990.0015","article-title":"DNA methylation and epigenetic inheritance","volume":"326","author":"Holliday","year":"1990","journal-title":"Philos. Trans. R. Soc. Lond."},{"key":"10.1016\/j.jim.2012.05.014_bb0480","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1021\/ja056726i","article-title":"Glutathione-mediated delivery and release using monolayer protected nanoparticle carriers","volume":"128","author":"Hong","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jim.2012.05.014_bb0485","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s10495-007-0087-3","article-title":"The inhibitors of apoptosis (IAPs) as cancer targets","volume":"129","author":"Hunter","year":"2007","journal-title":"Apoptosis"},{"key":"10.1016\/j.jim.2012.05.014_bb0490","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.taap.2008.02.007","article-title":"Factors affecting toxicity and efficacy of polymeric nanomedicines","volume":"229","author":"Igarashi","year":"2008","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.jim.2012.05.014_bb0495","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.seminoncol.2005.02.016","article-title":"Current management of advanced non\u2010small cell lung cancer: targeted therapy","volume":"32","author":"Isobe","year":"2005","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.jim.2012.05.014_bb0500","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2174\/138161208783885335","article-title":"Isoform-selective histone deacetylase inhibitors","volume":"14","author":"Itoh","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jim.2012.05.014_bb0505","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1118\/1.3002307","article-title":"The future of heavy ion radiotherapy","volume":"35","author":"Jakel","year":"2008","journal-title":"Med. Phys."},{"key":"10.1016\/j.jim.2012.05.014_bb0510","series-title":"Immunobiology 5: The Immune System in Health and Disease","author":"Janeway","year":"2001"},{"key":"10.1016\/j.jim.2012.05.014_bb0515","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/j.1349-7006.2009.01202.x","article-title":"Cytokine gene-mediated immunotherapy: current status and future perspectives","volume":"100","author":"Jinushi","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jim.2012.05.014_bb0520","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jtbi.2009.05.001","article-title":"On immunotherapiesandcancervaccinationprotocols: a mathematical modeling approach","volume":"259","author":"Joshi","year":"2009","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.jim.2012.05.014_bb1140","first-page":"573","article-title":"Why target apoptosis in cancer treatment?","volume":"2","author":"Kasibhatla1","year":"2003","journal-title":"Mol. Cancer Ther."},{"issue":"Suppl. 1","key":"10.1016\/j.jim.2012.05.014_bb0530","first-page":"4S","article-title":"Radiobiologic principles in radionuclide therapy","volume":"46","author":"Kassis","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jim.2012.05.014_bb0535","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.4049\/jimmunol.177.5.2862","article-title":"T helper lymphocytes rescue CTL from activation-induced cell death","volume":"177","author":"Kennedy","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb0540","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-065X.2008.00616.x","article-title":"Multiple roles for CD4+ T cells in anti-tumor immune responses","volume":"222","author":"Kennedy","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jim.2012.05.014_bb0545","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.184.4.1259","article-title":"Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands","volume":"184","author":"Kersh","year":"1996","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.jim.2012.05.014_bb0550","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/35101031","article-title":"Two genetic hits (more or less) to cancer","volume":"1","author":"Knudson","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jim.2012.05.014_bb0555","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ng.159","article-title":"Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation","volume":"40","author":"Kondo","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jim.2012.05.014_bb0560","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nbt0307-303","article-title":"Toll-free vaccines?","volume":"25","author":"Krieg","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jim.2012.05.014_bb0565","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.onc.1210911","article-title":"Toll-like receptor 9 (TLR9) agonists in the treatment of cancer","volume":"27","author":"Krieg","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.jim.2012.05.014_bb0570","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejphar.2009.10.011","article-title":"Epigenetics and cancer treatment","volume":"625","author":"Kristensen","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jim.2012.05.014_bb0575","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijpharm.2008.07.027","article-title":"Amine-functionalized gold nanoparticles as noncytotoxic and efficient intracellular siRNA delivery carriers","volume":"364","author":"Lee","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jim.2012.05.014_bb0580","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0952-7915(96)80106-3","article-title":"Processing and delivery of peptides presented by MHC class I molecules","volume":"8","author":"Lehner","year":"1996","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb0585","first-page":"188","article-title":"Mobile phones and head tumours: it is time to read and highlight data in a proper way","volume":"35","author":"Levis","year":"2011","journal-title":"Epidemiol. Prev."},{"key":"10.1016\/j.jim.2012.05.014_bb0590","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev.immunol.24.021605.090737","article-title":"Transforming growth factor-beta regulation of immune responses","volume":"24","author":"Li","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb0595","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4161\/cbt.6.5.3962","article-title":"Phi29 pRNA vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells","volume":"65","author":"Liu","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jim.2012.05.014_bb0600","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.4049\/jimmunol.178.5.2883","article-title":"Tumor evasion of the immune system by converting CD4+","volume":"178","author":"Liu","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb0605","first-page":"1","article-title":"Inhibition of tumor cellular proteasome activity by triptolide extracted from the Chinese medicinal plant \u2018thunder god vine\u2019","volume":"31","author":"Lu","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0610","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/38444","article-title":"Crystal structure of the nucleosome core particle at 2.8A resolution","volume":"389","author":"Luger","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.jim.2012.05.014_bb0615","first-page":"3239","article-title":"Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or flt3-ligand","volume":"60","author":"Mach","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0620","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.biocel.2008.08.020","article-title":"Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead","volume":"41","author":"Mai","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jim.2012.05.014_bb0625","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1158\/0008-5472.CAN-04-1261","article-title":"A-type-1 polarized dendritic cells, a novel immunization tool with optimized CTL-inducing activity","volume":"64","author":"Mailliard","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0630","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tips.2009.08.004","article-title":"Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer","volume":"30","author":"Malam","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jim.2012.05.014_bb0635","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1093\/emboj\/cdg263","article-title":"HBXIP functions as a cofactor of survivin in apoptosis suppression","volume":"22","author":"Marusawa","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.jim.2012.05.014_bb0640","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1071059","article-title":"The danger model: a renewed sense of self","volume":"296","author":"Matzinger","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jim.2012.05.014_bb0645","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.immuni.2007.11.003","article-title":"How do adjuvants work? Important considerations for new generation adjuvants","volume":"27","author":"McKee","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.jim.2012.05.014_bb0650","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.tips.2008.05.005","article-title":"Multilayered action mechanisms of CD137 (4-1BB)-targeted immunotherapies","volume":"29","author":"Melero","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jim.2012.05.014_bb0655","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/nrc2013","article-title":"Cancer as an evolutionary and ecological process","volume":"6","author":"Merlo","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jim.2012.05.014_bb0660","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00109-010-0708-0","article-title":"hSMG-1 is a granzyme B-associated stress-responsive protein kinase","volume":"89","author":"Meslin","year":"2011","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.jim.2012.05.014_bb0665","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ymeth.2011.06.009","article-title":"Targeted endoradiotherapy using nucleotides","volume":"55","author":"Morgenroth","year":"2011","journal-title":"Methods"},{"issue":"5","key":"10.1016\/j.jim.2012.05.014_bb0670","first-page":"555","article-title":"Gene therapy for cancer","volume":"81","author":"Mulherkar","year":"2001","journal-title":"Curr. Sci."},{"key":"10.1016\/j.jim.2012.05.014_bb0675","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","article-title":"YM155, a novel small-molecule survivin suppressant, induces regression of established human hormonerefractory prostate tumor xenografts","volume":"67","author":"Nakahara","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0680","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0304-3835(00)00600-5","article-title":"Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system","volume":"1611","author":"Nakayama","year":"2000","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jim.2012.05.014_bb0685","series-title":"An Introduction to Radiobiology","author":"Nias","year":"1998"},{"key":"10.1016\/j.jim.2012.05.014_bb0690","first-page":"1503","article-title":"Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma","volume":"21","author":"Ning","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jim.2012.05.014_bb0695","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2007-0236","article-title":"RNA-directed therapy: the next step in the miRNA revolution","volume":"131","author":"Novina","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.jim.2012.05.014_bb0700","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/1078-0432.CCR-08-0684","article-title":"Histone deacetylase 8 in neuroblastoma tumorigenesis","volume":"15","author":"Oehme","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0705","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ijpharm.2008.03.025","article-title":"Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors","volume":"359","author":"Ogawara","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jim.2012.05.014_bb0710","first-page":"19","article-title":"Cancer is a somatic cell pregnancy","volume":"7","author":"Old","year":"2007","journal-title":"Cancer Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb0715","first-page":"683","article-title":"Asbestos-related lung disease","volume":"75","author":"O'Reilly","year":"2007","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.jim.2012.05.014_bb0720","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF03027399","article-title":"Current status of cancer therapy with radiolabeled monoclonal antibody","volume":"19","author":"Oriuchi","year":"2005","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.jim.2012.05.014_bb0725","first-page":"413","article-title":"CD4+ T lymphocytes: a critical component of antitumor immunity","volume":"23","author":"Ostrand-Rosenberg","year":"2005","journal-title":"Cancer Invest."},{"issue":"6","key":"10.1016\/j.jim.2012.05.014_bb0730","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.semcancer.2004.06.009","article-title":"Infectious agents and cancer: criteria for a causal relation","volume":"14","author":"Pagano","year":"2004","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jim.2012.05.014_bb0735","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1078-0432.370.11.1","article-title":"CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma","volume":"11","author":"Palomba","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb1145","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1146\/annurev.immunol.21.120601.141135","article-title":"Does the immune system see tumors as foreign or self?","volume":"2t","author":"Pardoll","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb0745","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/ijc.21731","article-title":"The global health burden of infecion-associated cancers in the year 2002","volume":"118","author":"Parkin","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jim.2012.05.014_bb1150","article-title":"Tumor immunology: molecularly defined antigens and clinical applications","volume":"vol.1","author":"Parmiani","year":"2002"},{"key":"10.1016\/j.jim.2012.05.014_bb0755","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1038\/nm1210","article-title":"Targeting the innate immune response with improved vaccine adjuvants","volume":"11","author":"Pashine","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.jim.2012.05.014_bb0770","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1172\/JCI0214891","article-title":"Ribozymemediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis","volume":"1092","author":"Pennati","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jim.2012.05.014_bb0760","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1046\/j.1523-1747.2003.12082.x","article-title":"Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression","volume":"1204","author":"Pennati","year":"2003","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jim.2012.05.014_bb0765","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/carcin\/bgh107","article-title":"Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo","volume":"257","author":"Pennati","year":"2004","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jim.2012.05.014_bb0775","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/carcin\/bgm047","article-title":"Targeting survivin in cancer therapy: fulfilled promises and open questions","volume":"286","author":"Pennati","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jim.2012.05.014_bb0780","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/14728222.12.4.463","article-title":"Targeting survivin in cancer therapy","volume":"124","author":"Pennati","year":"2008","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jim.2012.05.014_bb0790","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jim.2012.05.014_bb0795","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000101564","article-title":"Helicobacter pylori and gastric cancer: the causal relationship","volume":"75","author":"Peter","year":"2007","journal-title":"Digestion"},{"key":"10.1016\/j.jim.2012.05.014_bb0800","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/la702782k","article-title":"Gold nanoparticles enhance the antileukemia action of a 6-mercaptopurine chemotherapeutic agent","volume":"24","author":"Podsiadlo","year":"2007","journal-title":"Langmuir"},{"key":"10.1016\/j.jim.2012.05.014_bb0805","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1021\/la0633841","article-title":"Water-soluble nitric oxide-releasing gold nanoparticles","volume":"23","author":"Polizzi","year":"2007","journal-title":"Langmuir"},{"key":"10.1016\/j.jim.2012.05.014_bb0810","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-0854.2005.00268.x","article-title":"Regulation of nuclear transport: central role in development and transformation?","volume":"6","author":"Poon","year":"2005","journal-title":"Traffic"},{"key":"10.1016\/j.jim.2012.05.014_bb0815","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0168-6445(03)00020-2","article-title":"Ribozymes: recent advances in the development of RNA tools","volume":"271","author":"Puerta-Fernandez","year":"2003","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.jim.2012.05.014_bb0820","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2008.05.010","article-title":"Preparation and in vitro evaluation of liposomal chloroquine diphosphate loaded by a transmembrane pH-gradient method","volume":"361","author":"Qiu","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jim.2012.05.014_bb0825","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3121\/cmr.3.4.221","article-title":"Lung cancer immunotherapy","volume":"3","author":"Raez","year":"2005","journal-title":"Clin. Med. Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0830","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/sj.bjc.6603649","article-title":"Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review","volume":"96","author":"Raza","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jim.2012.05.014_bb0835","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1200\/JCO.2003.06.041","article-title":"Current developments in cancer vaccines and cellular immunotherapy","volume":"21","author":"Ribas","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jim.2012.05.014_bb0840","first-page":"596","article-title":"Bortezomib: a novel therapy approved for multiple myeloma","volume":"1","author":"Richardson","year":"2003","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.jim.2012.05.014_bb0845","series-title":"SEER Cancer Statistics Review","first-page":"1975","year":"2007"},{"key":"10.1016\/j.jim.2012.05.014_bb0850","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1006\/smim.1997.0083","article-title":"DNA vaccines","volume":"9","author":"Robinson","year":"1997","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb0855","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ctrv.2009.05.003","article-title":"Survivin: a new target for anti-cancer therapy","volume":"35","author":"Ryan","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jim.2012.05.014_bb0865","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ni1178","article-title":"Naturally arising Foxp3\u2010expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self","volume":"6","author":"Sakaguchi","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb0870","doi-asserted-by":"crossref","first-page":"4258s","DOI":"10.1158\/1078-0432.CCR-040023","article-title":"Anti-vascular endothelial growth factor monoclonals in non\u2010small cell lung cancer","volume":"10","author":"Sandler","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0875","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/ni1420","article-title":"The innate signaling of dangers and the dangers of innate signaling","volume":"7","author":"Sansonetti","year":"2006","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb0880","first-page":"1002","article-title":"Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy","volume":"8","author":"Schabowsky","year":"2007","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.jim.2012.05.014_bb0885","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.yexmp.2009.01.010","article-title":"ProtEx\u2122 technology for the generation of novel therapeutic cancer vaccines","volume":"86","author":"Schabowsky","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.jim.2012.05.014_bb0890","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.seminoncol.2003.11.006","article-title":"Apoptosis in cancer \u2014 implications for therapy","volume":"31","author":"Schulze-Bergkamen","year":"2004","journal-title":"Semin. Oncol."},{"issue":"62\u201363","key":"10.1016\/j.jim.2012.05.014_bb0895","first-page":"66","article-title":"T cell anergy","volume":"269","author":"Schwartz","year":"1993","journal-title":"Sci. Am."},{"key":"10.1016\/j.jim.2012.05.014_bb0900","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2012.05.014_bb0905","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/0-306-47148-5_4","article-title":"Alcohol and cancer","volume":"14","author":"Seitz","year":"1998","journal-title":"Recent Dev. Alcohol."},{"key":"10.1016\/j.jim.2012.05.014_bb0910","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2008.12.034","article-title":"Synergy of 5-aza-2\u2032-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and \u2010independent prostate cancer cell lines","volume":"278","author":"Shang","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jim.2012.05.014_bb0920","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3322\/canjclin.56.4.226","article-title":"Targeted therapy of cancer: new prospects for antibodies and immunoconjugates","volume":"56","author":"Sharkey","year":"2006","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jim.2012.05.014_bb0915","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.addr.2008.04.011","article-title":"Use of antibodies and immunoconjugates for the therapy of more accessible cancers","volume":"60","author":"Sharkey","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jim.2012.05.014_bb0925","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/15058","article-title":"Advances in vaccine adjuvants","volume":"17","author":"Singh","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jim.2012.05.014_bb0930","first-page":"4067","article-title":"A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity","volume":"63","author":"Singh","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0935","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1158\/1078-0432.CCR-07-1565","article-title":"Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin","volume":"141","author":"Singh","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0940","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1002\/anie.200504599","article-title":"Laser-induced release of encapsulated materials inside living cells","volume":"45","author":"Skirtach","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jim.2012.05.014_bb0945","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1158\/0008-5472.CAN-04-3787","article-title":"Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer","volume":"65","author":"So","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0950","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejogrb.2006.07.057","article-title":"Survivin gene RNA interference inhibits proliferation, induces apoptosis, and enhances radiosensitivity in HeLa cells","volume":"1361","author":"Song","year":"2008","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.jim.2012.05.014_bb0955","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1172\/JCI23373","article-title":"Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909","volume":"115","author":"Speiser","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jim.2012.05.014_bb0960","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/sj.bjc.6604932","article-title":"Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo","volume":"100","author":"Steele","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jim.2012.05.014_bb2000","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0027-5107(97)00276-5","article-title":"Cancer prevention: past, present, future","volume":"402","author":"Sugimura","year":"1998","journal-title":"Mutat. Res."},{"key":"10.1016\/j.jim.2012.05.014_bb0965","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1289\/ehp.1103693","article-title":"International Commission for Non-Ionizing Radiation Protection Standing Committee on Epidemiology. Mobile phones, brain tumors, and the interphone study: where are we now?","volume":"119","author":"Swerdlow","year":"2011","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.jim.2012.05.014_bb0970","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1172\/JCI34409C1","article-title":"Regression of human kidney cancer following allogeneic stem cell transplantation is associated with reconition of an HERV-E antigen by T cells","volume":"118","author":"Takahashi","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jim.2012.05.014_bb0975","first-page":"623","article-title":"Therapeutic antitumor response to cervical cancer in mice immunized with U14 vaccines transfected with costimulatory B7 gene","volume":"114","author":"Tao","year":"2001","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.jim.2012.05.014_bb0980","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/sj.cgt.7700526","article-title":"Transcellular transfer of active HSV-1 thymidine kinase mediated by an 11-amino-acid peptide from HIV-1 Tat","volume":"10","author":"Tasciotti","year":"2003","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jim.2012.05.014_bb0985","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.coph.2007.09.010","article-title":"Ubiquitin\u2013proteasome system as a modulator of cell fate","volume":"8","author":"Thompson","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jim.2012.05.014_bb0990","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1126\/science.8456302","article-title":"Heterologous protection against influenza by injection of DNA encoding a viral protein","volume":"259","author":"Ulmer","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.jim.2012.05.014_bb0995","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm1405","article-title":"Eradication of established tumors in mice by a combination antibody-based therapy","volume":"12","author":"Uno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.jim.2012.05.014_bb1000","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1074-7613(00)80478-1","article-title":"The Fas\/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens","volume":"8","author":"Van Parijs","year":"1998","journal-title":"Immunity"},{"issue":"Suppl. 4","key":"10.1016\/j.jim.2012.05.014_bb1005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","article-title":"The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective","volume":"15","author":"Venook","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.jim.2012.05.014_bb1010","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/bies.20734","article-title":"The role of ATF-2 in oncogenesis","volume":"30","author":"Vlahopoulos","year":"2008","journal-title":"Bioessays"},{"key":"10.1016\/j.jim.2012.05.014_bb1015","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"29523","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jim.2012.05.014_bb1020","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2174\/092986706776872871","article-title":"Protein transduction: cell penetrating peptides and their therapeutic applications","volume":"13","author":"Wagstaff","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jim.2012.05.014_bb1025","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejphar.2009.06.069","article-title":"Nuclear drug delivery to target tumour cells","volume":"625","author":"Wagstaff","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jim.2012.05.014_bb1030","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2007-07-104604","article-title":"Differential costimulation through CD137 (4-1BB) restores proliferation of human virus-specific \u201ceffector memory\u201d (CD28(\u2212) CD45RA(HI)) CD8(+) T cells","volume":"110","author":"Waller","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jim.2012.05.014_bb1035","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.282.5388.476","article-title":"Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine","volume":"282","author":"Wang","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jim.2012.05.014_bb1040","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/092986607780090874","article-title":"Radiolabeled peptides and proteins in cancer therapy","volume":"14","author":"Wangler","year":"2007","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.jim.2012.05.014_bb1045","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/CJI.0b013e3181611420","article-title":"Phase 1 trial of intranodal injection of a Melan-A\/MART-1 DNA plasmid vaccine in patients with stage IV melanoma","volume":"31","author":"Weber","year":"2008","journal-title":"J. Immunother."},{"key":"10.1016\/j.jim.2012.05.014_bb1050","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1158\/0008-5472.CAN-07-6051","article-title":"Cancer immunotherapy using in vitro genetically modified targeted dendritic cells","volume":"68","author":"Wei","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jim.2012.05.014_bb1055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.imlet.2007.09.012","article-title":"Plasmid DNA- and messenger RNA-based anti-cancer vaccination","volume":"115","author":"Weide","year":"2008","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.jim.2012.05.014_bb1060","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1749-6632.2009.05039.x","article-title":"Mitochondrial metabolism and cancer. Hypoxia and consequences","volume":"1177","author":"Weinberg","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jim.2012.05.014_bb1065","first-page":"277","article-title":"Genetic vaccines","volume":"341","author":"Weiner","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2012.05.014_bb1070","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/jnci\/djg040","article-title":"Annual report to the nation on the status of cancer, 1975\u20132000, featuring the uses of surveillance data for cancer prevention and control","volume":"95","author":"Weir","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jim.2012.05.014_bb1075","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/09553000902985144","article-title":"History and development of radiation-protective agents","volume":"85","author":"Weiss","year":"2009","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.jim.2012.05.014_bb1155","series-title":"Hepatitis B. Factsheet No 204","author":"WHO","year":"2008"},{"key":"10.1016\/j.jim.2012.05.014_bb1160","series-title":"Hepatitis C. Factsheet No 164","author":"WHO","year":"2011"},{"key":"10.1016\/j.jim.2012.05.014_bb1090","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.jim.2012.05.014_bb1095","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ces.2005.06.019","article-title":"Inorganic nanoparticles as carriers for efficient cellular delivery","volume":"61","author":"Xu","year":"2006","journal-title":"Chem. Eng. Sci."},{"key":"10.1016\/j.jim.2012.05.014_bb1100","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2217\/nnm.09.9","article-title":"Quantum dots and their potential biomedical applications in photosensitization for photodynamic therapy","volume":"4","author":"Yaghini","year":"2009","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jim.2012.05.014_bb1105","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nbt1390","article-title":"Engineered lentivector targeting of dendritic cells for in vivo immunization","volume":"26","author":"Yang","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jim.2012.05.014_bb1110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cytogfr.2008.04.004","article-title":"Targeting tumors with LIGHT to generate metastasis-clearing immunity","volume":"19","author":"Yu","year":"2008","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jim.2012.05.014_bb1120","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1124\/jpet.103.059378","article-title":"The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells","volume":"3082","author":"Zhang","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jim.2012.05.014_bb1115","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.4049\/jimmunol.181.5.3690","article-title":"Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell\/tumor fusion vaccine efficacy","volume":"181","author":"Zhang","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb1125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jim.2012.05.014_bb1130","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejphar.2009.05.035","article-title":"Endoradiotherapy in cancer treatment \u2014 basic concepts and future trends","volume":"625","author":"Zoller","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jim.2012.05.014_bb1135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc1586","article-title":"Immunosuppressive networks in the tumour environment and their therapeutic relevance","volume":"5","author":"Zou","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jim.2012.05.014_bb1165","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1126\/science.1659743","article-title":"Viruses in human cancers","volume":"254","author":"zur Hausen","year":"1991","journal-title":"Science"}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175912001524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175912001524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:50:47Z","timestamp":1687481447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175912001524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":227,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0022175912001524"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2012.05.014","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}